PMID- 12891305
OWN - NLM
STAT- MEDLINE
DCOM- 20031223
LR  - 20181130
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 43
IP  - 6
DP  - 2003
TI  - [Non ST elevation acute coronary syndrome: early use of pravastatin or 
      atorvastatin is associated with divergent changes of parameters of hemostasis].
PG  - 4-13
AB  - PURPOSE: To find out whether pravastatin and atorvastatin rapidly (in 1-2 weeks) 
      and similarly affect hemostasis in patients with non-ST elevation acute coronary 
      syndrome (NSTEACS). METHODS: Ninety aspirin and heparin treated patients with 
      NSTEACS were randomized <24 hours from pain onset to open pravastatin 40 mg/day 
      (n=31), atorvastatin 10 mg/day (n=30) or atorvastatin 40 mg/day (n=29). At 
      baseline, on days 7, 14 plasma thrombin-antithrombin complex (TAT), prothrombin 
      fragments 1+2 (F1+2), D-dimer, von Willebrand factor (vWF) were measured by 
      ELISA. Results were compared with data from controls (n=18) of another randomized 
      study on similarly treated patients. RESULTS: In all treatment groups levels of 
      low-density lipoprotein cholesterol (LDLCH) were lowered by days 7 (p<0,01) and 
      14 (p<0,01 vs. baseline and for both atorvastatin groups vs. day 7). In 
      pravastatin group levels of TAT and F1+2 decreased, while vWF level increased. In 
      atorvastatin groups levels of TAT and F 1+2 increased while level of vWF 
      decreased. Contrary to pravastatin group changes in atorvastatin treated patients 
      more resembled those in controls not receiving lipid lowering drugs. Changes of 
      both LDLCH and TCH directly correlated only with changes of vWF (r=0.23, p=0.03 
      and r=0.25, p=0.02, respectively). No consistent changes of D-dimer occurred. 
      CONCLUSION: Early use of atorvastatin and pravastatin in patients with NSTEACS 
      was associated with rapid divergent changes of some hemostatic parameters. Except 
      lowering of von Willebrand factor changes in atorvastatin treated patients more 
      resembled those in controls not receiving lipid lowering drugs. Von Willebrand 
      factor was the only parameter which changes weakly but significantly correlated 
      with changes of CH and LDL CH levels.
FAU - Pokrovskaia, E V
AU  - Pokrovskaia EV
FAU - Gratsianskii, N A
AU  - Gratsianskii NA
FAU - Averkov, O V
AU  - Averkov OV
FAU - Slavina, N N
AU  - Slavina NN
FAU - Vaulin, N A
AU  - Vaulin NA
FAU - Deev, A D
AU  - Deev AD
LA  - rus
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Ostryi koronarnyi sindrom bez pod"emov segmenta ST na EKG: raznonapravlennye 
      izmeneniia pokazatelei gemostaza pri rannem primenenii atorvastatina i 
      pravastatina.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Anticholesteremic Agents/*pharmacology/therapeutic use
MH  - Atorvastatin
MH  - Coronary Disease/diagnosis/drug therapy/*physiopathology
MH  - Electrocardiography
MH  - Female
MH  - Heptanoic Acids/*pharmacology/therapeutic use
MH  - Homeostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pravastatin/*pharmacology/therapeutic use
MH  - Pyrroles/*pharmacology/therapeutic use
MH  - Syndrome
MH  - Time Factors
EDAT- 2003/08/02 05:00
MHDA- 2003/12/24 05:00
CRDT- 2003/08/02 05:00
PHST- 2003/08/02 05:00 [pubmed]
PHST- 2003/12/24 05:00 [medline]
PHST- 2003/08/02 05:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2003;43(6):4-13.